Synthetic Biologics Inc. (NYSEMKT:SYN) belongs to Healthcare sector. Its weekly performance is 40.35%. On last trading day company shares ended up $4.00. Synthetic Biologics Inc. (NYSEMKT:SYN) distance from 50-day simple moving average (SMA50) is 66.50%. On 29 June, Synthetic Biologics Inc. (NYSEMKT:SYN) reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares increased 2.35% in last trading session and ended the day at $91.63. ESPR return on assets is -26.70%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) quarterly performance is -11.68%. On 7 July, Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced the U.S. Food and Drug Administration (FDA) has removed the 240 mg partial clinical hold on ETC-1002 (bempedoic acid). This action by FDA will now allow ETC-1002 to be used at doses above 240 mg in clinical studies. Esperion plans to initiate the Phase 3 clinical program for ETC-1002 in the fourth quarter of this year using the already optimized 180 mg dose.
On 14 July, Great Plains Energy Incorporated (NYSE:GXP) shares moved down -0.40% and was closed at $25.10. GXP EPS growth in last 5 year was 6.20%. Great Plains Energy Incorporated (NYSE:GXP) year to date (YTD) performance is -10.01%. Great Plains Energy Incorporated (NYSE:GXP) had its price target lowered by SunTrust from $26.00 to $25.00 in a research note issued to investors on Monday. The firm currently has a neutral rating on the stock.
Gilead Sciences Inc. (NASDAQ:GILD) ended the last trading day at $117.36. Company weekly volatility is calculated as 1.58% and price to cash ratio as 15.27. Gilead Sciences Inc. (NASDAQ:GILD) showed a weekly performance of 1.94%.On 1 July, Gilead Sciences Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older.